Anti-Factor IX antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution

Not available outside of the UK & Ireland.

Application

Anti-Factor IX antibody produced in rabbit has been used in immunoblotting and Gla enzyme-linked immunosorbent assay (ELISA).

Biochem/physiol Actions

Hereditary deficiencies or dysfunctions of factor IX cause hemophilia B or "Christmas Disease"(the surname of the first family described).A disulfide bond in factor IX connects the N-terminal sequence (light chain) of factor IX to the C-terminal sequence (heavy chain).Factor IX possesses higher sensitivity, hence even tiny amounts of residual intact can be visualized by F0652.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Factor IX is a 55 kDa, single chain, vitamin K-dependent plasma zymogen. Factor IX is synthesized in liver parenchymal cells and requires a post-translational, vitamin K-dependent, modification in order to become a mature plasma zymogen. Factor IX concentration in human plasma ranges between 2.5-5 mg/ml and its half-life is ~24 hr. Human factor IX gene is about 40 kb in size and is localized at the distal end of the X-chromosome.

Four and a half LIM domains protein 1 is a protein encoded by the FHL1 gene in humans and is located on human chromosome Xq27.2. Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system. It belongs to peptidase family S1 and its deficiency causes hemophilia B. The proteins belong to a novel family of LIM proteins that are expressed in human skeletal muscle. FHL1 gene is related to carcinogenesis and its inactivation is a frequent event during oral carcinogenesis. FHL1 downregulation in oral squamous cell carcinoma (OSCC) occurs through DNA methylation of the promoter region rather than histone deacetylation or mutation.

Immunogen

human factor IX

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide

Specificity

Specifically reacts with human factor IX. The antibody detects human factor IX in both reduced and non-reduced normal human plasma.